Opko has until July 5 to comment on the proposed non-coverage local coverage determination, the most recent development in the test's twisted Medicare narrative.
The collaboration will use Protagen's SeroTag technology to predict patient response to immunotherapy treatment and to monitor patients for adverse effects.
Service revenues were down 8 percent year over year, product revenues grew 26 percent, and revenues from the transfer of intellectual property inched up less than 1 percent.
The USPSTF said that men aged 55 to 69 should decide in discussions with their clinicians whether to undergo periodic PSA screening.
The company had total revenues of $193.5 million during the quarter, driven by continued increases in revenue and test volume for its more recently launched and acquired tests.
Test volume and revenues increased in the US, especially in prostate cancer. Meanwhile, international test volume was down but corresponding revenue increased.
The firm presented on its pancreatic, breast, and prostate cancer programs, the latter of which is moving through clinical validation toward commercialization.
The firm said total test volumes rose 55 percent during the quarter, and test volumes for its SelectMDx liquid biopsy test nearly tripled in Europe.
Pivoting from a technology that it deemed wasn't robust enough, Confer Health is now designing a platform to enable broad-scale testing at home.
In developing the new tools, Google trained artificial intelligence algorithms to aid pathologists in making breast and prostate cancer diagnoses.